A Single-center, Randomized, Double-blind, Placebo-controlled and Single-center, Randomized, Open, Double-crossed Food Impact Trial to Evaluate the Safety, Tolerability, Pharmacokineticof GP681 Tablets in Healthy Subjects
Latest Information Update: 02 Feb 2021
At a glance
- Drugs GP 681 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Jiangxi Qingfeng Pharmaceutical
- 02 Feb 2021 New trial record